• Explore /
  • Poster
  • / Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.

Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.

Abstract Poster

Authors

null

yueyun chen

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

yueyun chen , Zhen-Yu Ding , Yong Yuan , Yu-Shang Yang , Zhen Lin , Jiangfang Tian , Ting Liu , Zheng Yue , Hua-Shan Shi , Yang Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2200064848

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 352)

DOI

10.1200/JCO.2024.42.3_suppl.352

Abstract #

352

Poster Bd #

G13

Abstract Disclosures

Similar Posters

First Author: Hailiang Zhang

First Author: Lei Liu

First Author: Mian Wang

First Author: Min Hee Hong